Cadila pharma unveils biosimilar Rituximab under brand name Ritucad
Ritucad is used in the treatment of Non-Hodgkin's lymphoma( a type of blood-related cancer)
Ahmedabad: Ahmedabad-based Cadila Pharmaceuticals Limited has announced the launch of biosimilar Rituximab for the Indian market.
Biosimilar Rituximab is used for the treatment of blood cancer and rheumatoid arthritis, and will be launched under the brand name Ritucad™.
Biosimilar products are manufactured from the DNA of living organisms. Biosimilar products are safe and more efficacious compared to conventional treatment medicines.
Ritucad™ is used in the treatment of Non-Hodgkin's lymphoma (a type of blood-related cancer). Every year there are more than 28,000 new cases of Lymphoma in India.
Ritucad™ is the second biosimilar in a series of biosimilar products planned by the organization this year and will be made available in a single-dose vial of two strengths, 100 mg and 500mg.
Cadila Pharmaceuticals Ltd has recently launched Bevasizumab biosimilar which is a humanized monoclonal antibody, recommended in multiple indications under the brand name Bevaro™.
The company has recently concluded and cleared USFDA inspection successfully in February 2020.
Cadila Pharmaceuticals is a multinational research-based pharmaceutical group in India with more than 6 decades of experience.